Evidence map›Paper›PMID 22083345›Full record

Trial reportCancer immunology, immunotherapy : CII2012

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.

Mark J Dobrzanski, Kathleen A Rewers-Felkins, Khaliquzzaman A Samad, Imelda S Quinlin, Catherine A Phillips, William Robinson, David J Dobrzanski, Stephen E Wright

Abstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph

Trial report in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Clonally expanded EOMESNature immunology · 2021
    Observational
  9. IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.Advances in experimental medicine and biology · 2021
    Review
  10. Monosexual Cercariae ofFrontiers in microbiology · 2020
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Targeted immune therapy of ovarian cancer.Cancer metastasis reviews · 2015
    Review
  16. TGFβ in T cell biology and tumor immunity: Angel or devil?Cytokine & growth factor reviews · 2014
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mark J DobrzanskiDepartment of Internal Medicine, Texas Tech University School of Medicine, Amarillo, TX 79106, USA. mark.dobrzanski@ttuhsc.edu
Kathleen A Rewers-Felkins
Khaliquzzaman A Samad
Imelda S Quinlin
Catherine A Phillips
William Robinson
David J Dobrzanski
Stephen E Wright
Texas Tech University · USBristol Hospital · USTexas Tech University Health Sciences Center · US

Funding

Cytotoxic T Lymphocyte Immunotherapy for Ovarian CancerR21CA089883 · NCI · DON AND SYBIL HARRINGTON CANCER CENTER · PI ROBINSON, WILLIAM R · 2001 to 2002
$245k
NCI NIH HHS 1R21CA89883-01A1NCI NIH HHS R21 CA089883
6 · The paper itself

Abstract

Adoptive T cell therapy for cancer patients optimally requires participation of CD4 T cells. In this phase I/II study, we assessed the therapeutic effects of adoptively transferred IL-10- and IFN-γ-producing CD4 effector cells in patients with recurrent ovarian cancer. Using MUC1 peptide and IL-2 for ex vivo CD4 effector cell generation, we show that three monthly treatment cycles of autologous T cell restimulation and local intraperitoneal re-infusion-modulated T cell-mediated immune responses that were associated with enhanced patient survival. One patient remains disease-free, another patient experienced prolonged survival for nearly 16 months with recurrent disease, and two patients expired within 3-5 months following final infusion. Prolonged survivors showed elevated levels of systemic CD3(+)CD4(+)CD25(+) and CD3(+)CD4(+)CD25(-) T cells when compared to that of pre-treatment levels and similarly treated short-term survivors. Such cell populations among these patients contained variable levels of "Inducible" Tr1 (CD4(+)CD25(-)FoxP3(-)IL-10(+)) and "Natural" (CD4(+)CD25(+)CD45RO(+)FoxP3(+)) TReg cell numbers and ratios that were associated with prolonged and/or disease-free survival. Moreover, peptide-restimulated T cells from these patients showed an elevation in both IFN-γ production, memory cell phenotype, and select TNF family ligands associated with enhanced T cell survival and apoptosis-inducing activities. This suggests that intraperitoneally administered Th1-like cells, producing elevated levels of IL-10, may require and/or induce differential levels of distinct systemic TReg subpopulations that influence, in part, long-term tumor immunity and enhanced memory/effector CD4-mediated therapeutic potentials. Furthermore, treatment efficacy and enhanced memory cell phenotype did not appear to be dependent on TReg cell numbers but upon ratios of "Inducible" and "Natural" TReg subpopulations.

Indexed as

ImmunotherapyAgedFemaleHumansInterferon-gammaInterleukin-10Middle AgedMucin-1Ovarian NeoplasmsPhenotypeT-Lymphocytes, RegulatoryInterferon-gammaInterleukin-10Mucin-1

Identifiers

PMID22083345
PMCPMC3315597
OpenAlexW2090592826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.